PHGE חוב כולל להון BiomX

BiomX Inc. (PHGE) develops bacteriophage-based drugs to combat skin and intestinal pathologies, mitigating risks through a diverse range of trial stages. This price action chart on GURU.Markets shows that the debt-to-equity ratio is 0.32, while the company withstands pressure from the creators of modern antibiotics. The business is currently focusing on the integration of acquired assets and scientific alliances.

Since BiomX Inc. (PHGE) outsources bacteriophage production to third-party contractors, the company's financial stability depends on the balance between borrowed funds and equity. The current debt-to-equity ratio, equal to 0.32, reflects the degree of leverage: the ratio of total liabilities to equity determines the default risk during liquidity crunches or the business's ability to scale amid interest rate volatility.